ESMO ESMO 2023: Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 study By ONA Editor October 23, 2023 No Comments Share Tweet Pinterest LinkedIn Tumblr Email + Share. Twitter Facebook Pinterest LinkedIn Tumblr Email
FDA grants accelerated approval to selpercatinib for paediatric patients two years and older with RET-altered metastatic thyroid cancer or solid tumours June 4, 2024 0